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Schizophrenia is a highly heritable disorder with a polygenic pattern of inheritance and a
population prevalence of B1%. Previous studies have implicated synaptic dysfunction in
schizophrenia. We tested the accumulated association of genetic variants in expert-curated
synaptic gene groups with schizophrenia in 4673 cases and 4965 healthy controls, using
functional gene group analysis. Identifying groups of genes with similar cellular function
rather than genes in isolation may have clinical implications for finding additional drug targets.
We found that a group of 1026 synaptic genes was significantly associated with the risk of
schizophrenia (P=7.6 10
 11) and more strongly associated than 100 randomly drawn,
matched control groups of genetic variants (P<0.01). Subsequent analysis of synaptic
subgroups suggested that the strongest association signals are derived from three synaptic
gene groups: intracellular signal transduction (P=2.0 10
 4), excitability (P=9.0 10
 4) and
cell adhesion and trans-synaptic signaling (P=2.4 10
 3). These results are consistent with a
role of synaptic dysfunction in schizophrenia and imply that impaired intracellular signal
transduction in synapses, synaptic excitability and cell adhesion and trans-synaptic signaling
play a role in the pathology of schizophrenia.
Molecular Psychiatry (2012) 17, 996–1006; doi:10.1038/mp.2011.117; published online 20 September 2011
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Introduction
Schizophrenia is a chronic and debilitating brain
disorder that affects B1% of the population.
1 It is
characterized by delusional beliefs, hallucinations,
disordered speech and deficits in emotional and
social behavior (see, for example, Mowry et al.
2) and
is highly familial with heritability estimates of 81%.
3
The genome-wide association (GWA) studies have
explained only a small amount of genetic variance in
schizophrenia and are limited in power because of the
many tests performed and do not necessarily lead to
knowledge about molecular mechanisms of a clinical
trait. In addition, the strongest associated variants—
when part of a pathway—might not be the best drug
target for therapeutic intervention, and identifying
variants in the same cellular pathway or functionally
related gene group may help in finding additional
drug targets. Recent GWA studies for schizophrenia
have implicated the major histocompatibility com-
plex on 6p21.2–22.1, neurogranin (NRGN) and tran-
scription factor 4 (TCF4).
4–6 In addition, they have
provided molecular genetic evidence for a substantial
polygenic component, implicating a large number of
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www.nature.com/mpsingle-nucleotide polymorphisms (SNPs) of very
small effect in the etiology of schizophrenia.
4 Some
of these exceed genome-wide significance, but the
currently available sample sizes are insufficient to
detect these effects.
7 Therefore, SNPs in the
5 10
 8 1 10
 6 band are a mix of SNPs, some of
true effect and some that are false positives. Exactly
what is the mix of true/false positives is currently
unknown. Gene set or pathway analysis involves
testing for the combined effect of multiple SNPs,
which individually may have a very small effect that
does not reach significance. By using a competitive
testing scheme, associations of gene sets with a
disease are corrected for false positives.
It seems likely that the substantial polygenic
component involves SNPs that are not distributed
randomly across the genome but are distributed
across genes that share a common biological function
or pathway.
8–11 Recent pathway analyses provided
evidence for the importance of the cell adhesion
molecule pathway in schizophrenia,
12 as well as
the glutamate metabolism, transforming growth fac-
tor-b signaling and tumor-necrosis factor receptor-1
pathways.
10
Pathway analysis is predicated upon accurate
pathway definitions and validated assignment of
genes to pathways. However, many of the available
databases used for pathway definitions are not
optimally annotated and the same pathways can be
differentially defined across databases. Classically
defined pathways are usually not independent, as the
same genes, especially the end points, are often active
in different pathways. Consequently, genetic variation
that affects the expression or function of genes in
different pathways may have similar consequences,
have similar impact on pathogenesis and show
similar disease association. Genes may also be
grouped according to shared cellular function (see,
for example, Ruano et al.
11). Such ‘functional gene
grouping’ goes across the traditionally defined biolo-
gical pathways as it groups genes based on similar
cellular function, and not based on a cascade of
induced events, as in biological pathways. We
recently proposed such a functional gene grouping
approach to test for the combined effect of genetic
variants in genes with shared cellular function in the
synapse using a manually curated database of gene
function based on both experimentation and data
mining.
11 Using this approach, it was found that one
relay element involved in many pathways (G pro-
teins) was associated with cognitive traits, a strong
association, which had remained unnoticed by tradi-
tional single-marker analysis.
11
Numerous statistical methods are available to
evaluate the enrichment of selected pathways or
functional gene groups for selected traits, including,
for example, the Gene Set Enrichment Analysis,
13,14
testing for overrepresentation of categories of genes,
9
the SNP ratio test,
12 hypergeometric tests (see, for
example, Jia et al.
10) or the S-log(P) method combined
with permutation.
11 Most of these methods correct for
linkage disequilibrium between SNPs, the number of
SNPs per gene, gene size and multiple testing of
independent pathways. Permutation is generally used
to determine how likely a given result is if the null
hypothesis of no association is true. However, the
more genes are present in the defined gene group, the
more likely it becomes to observe smaller P-values. In
addition, generally these methods do not test how
unique a certain result is given the polygenic nature
of many studied traits. The latter involves testing
whether a given pathway is significantly associated
with a trait because it (1) includes a lot of genes and
the trait is polygenic in nature or (2) because of the
biological function of the pathway. This can be
resolved by testing for association of matched-control
gene groups in comparison with the targeted gene
groups or pathways.
The purpose of the current study is to apply a
functional gene group approach to detect well-
annotated functional gene groups that are important
to the risk of schizophrenia. The synaptic hypothesis
of schizophrenia
15–18 is one of the leading hypotheses
in the field of schizophrenia. Recent genetic findings
underscore the importance of synaptic dysfunction in
schizophrenia.
6,12 Therefore, we formally tested
whether the group of genes involved in pre- and
post-synaptic functioning is related to schizophrenia,
and whether this group is more strongly related than
randomly drawn matched sets of genes, using a
‘competitive’ control method.
19 Apart from testing
all synaptic genes for an association with the risk of
schizophrenia, we also tested 17 subgroups of
synaptic functioning, defined based on data mining
and experimentation.
11 We used the data genotyped
within the International Schizophrenia Consortium
(ISC) case–control sample
4 and the Genetic Associa-
tion Information Network (GAIN) schizophrenia
data set.
Materials and methods
Participants and genotyping
The ISC case–control sample includes 3322 cases and
3587 controls (European ancestry), derived from
seven different collection sites and is described in
detail elsewhere.
4 Subjects were genotyped on Affy-
metrix 5.0 or 6.0 SNP arrays (Affymetrix, Santa Clara,
CA, USA), and 300523 SNPs passed quality control
for the ISC_affy5 sample (3353 subjects) and 717126
SNPs for the ISC_affy6 sample (3556 subjects).
The GAIN schizophrenia case–control sample has
been described elsewhere
5,20 and has been down-
loaded from dbGAP (phs000021.v2.p1). Briefly, this
sample included 1351 cases and 1378 controls of
European ancestry. All individuals were genotyped
on the Affymetrix 6.0 array, and 727872 SNPs were
available for analysis. The quality control procedures
followed those described in Shi et al.
5 The GAIN and
two ISC (affy5 and affy6) are independent and non-
overlapping, and together contain 9638 individuals
(4673 cases/4965 controls) of European ancestry.
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Synaptic functional gene group definition was based
on cellular function as determined by previous
protein identification and data mining for synaptic
genes and gene function.
11 Genes were considered
‘synaptic’ based on proteomic analysis of synaptic
preparations.
21 In case of presynaptic genes, an
additional expert curation was performed because
only few analyses of highly purified preparations are
currently available for the presynaptic proteome,
except synaptic vesicles.
22 Hence, presynaptic genes
not covered by Takamori et al.
22 were manually
curated using published functional data and a
cumulative scoring paradigm with the following set
of weighted criteria: null mutation produces a
synaptic phenotype; activation of the gene product
(for example, receptor) or blockade thereof directly
modulates synaptic function; and immunoelectron
microscopy detects gene product in the synapse.
More than 500 PubMed entries were manually
screened. Although this approach introduces a bias
toward well-studied genes, this is inherent to creating
functional gene groups, as functional grouping is by
definition limited to those genes for which functional
data are available. Synaptic genes were subdivided
into 17 functional groups based on shared cellular
function (a full listing of genes assigned to functional
groups is provided in the Supplementary Material,
Table S4).
SNP assignment
All SNPs that survived quality control in the ISC and
GAIN samples were mapped to genes on the basis of
NCBI (National Center for Biotechnology Information)
human assembly build 36.3 and dbSNP release 129
(following Holmans et al.
9). For the definition of the
gene boundaries we downloaded the ‘seq_gene.md’
file from the FTP website of NCBI. From this list of
records we deleted genes coded as pseudo in the
column ‘feature_type’. Subsequently, we selected the
records with gene as ‘feature_type’ and reference as
‘group_label’. For these records, we assigned SNPs to
genes when annotated between ‘chr_start’ (transcrip-
tion start site) and ‘chr_stop’ (transcription stop site).
Association analysis
SNP association analyses were carried out using
additive models of allele counts. For the ISC data set,
a correction for clustering within stratum (collection
site) was performed.
4 Cochran–Mantel–Haenszel tests
implemented in PLINK were used for the association
analyses (PLINK, Boston, MA, USA). All analyses
were carried out separately for the ISC_affy5, ISC_affy6
and the GAIN data sets. Empirical P-values from the
three data sets were combined by Stouffer’s weighted
Z-transform method
23 to obtain an overall P-value.
Evaluating the combined effect of all SNPs in a
functional gene group: the S-log(P) method
We summed the logarithm of the reciprocal of the
P-values (denoted as S-log(P) method)
24,25 as previously
applied to gene group analysis
11 to determine the
significance of the combined effect of SNPs annotated
to genes in a functional group. The S-log(P) method
combines P-values from association analyses within a
group of genetic variants, then calculates the –log10 of
each P-value, and sums over all P-values in a group to
obtain the S-log(P) test statistic. To allow unbiased
interpretation of the S-log(P) test statistic, 10000
permutations were conducted, which are implicitly
conditional on linkage disequilibrium, sample size,
gene size, the number of SNPs per gene and the
number of genes per group, by permuting affection
status over genotypes. With this permutation proce-
dure, only the relation between any genetic variant
and affection status was disconnected, whereas
linkage disequilibrium structure was kept intact. In
addition, each group of genetic variants included the
same (numbers of) SNPs and genes and had the same
sample size as the original data set. For each
permutation, we obtained the S-log(P) for each
functional group and then compared the observed
S-log(P) of a group with the empirical P-value
distribution by calculating the proportion of S-log(P)
in the permuted data sets that was higher than the
observed S-log(P).
Controlling for known polygenic effect on
schizophrenia
The permutation approach described above provides
information on how likely a given value of the
combined effect of all SNPs in a group of genes is
under the null hypothesis of no association of any
SNP included in the functional group with the risk of
schizophrenia (that is, self-contained testing).
19 We
additionally applied matched-control methods (that
is, competitive testing) that allow to test whether
randomly drawn groups of SNPs/genes would pro-
vide an equally or more significant (combined)
empirical P-value as compared with the combined
P-value from the group of synaptic genes. We created
control gene groups matched for the number of genes
(method 1) and groups that were matched for the
effective number of SNPs, which could be drawn from
all genic and nongenic SNPs (method 2), from genic
SNPs only (method 3), from nongenic SNPs only
(method 4) or from genic SNPs in brain-expressed
genes only (method 5). The effective number of SNPs
denotes the number of independent SNPs that is
consistent with the empirical mean and variance of
the distribution of the test statistic under the null
hypothesis of no association
26 (see Supplementary
Material, section 2). Matching for the number of genes
as well as for the effective number of SNPs in a
functional gene group would be ideal but is highly
limited as there will only be a few (<5) sets of gene
groups that can be created when the original group of
genes is large (1026 in our case). We thus created
matched control groups following the five methods
described above, each testing slightly different null
hypotheses (see Table 1).
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matched control groups were drawn. For each draw
we carried out an association analysis of all SNPs in
the matched control group in each of the three data
sets, calculated the S-log(P) and then conducted
10000 permutations of the data set to determine the
empirical P-value of each of the 100 matched control
groups of genes in each data set, similar to the actual
analysis with the group of synaptic genes. These
empirical P-values were combined across the three
data sets using Stouffer’s weighted Z-transform
method.
23 For the five control designs, we thus
obtained five sets of 100 combined empirical
P-values. We then calculated how often the true
combined empirical P-value (from the synaptic gene
group) was higher than the combined empirical
P-value from the matched control groups and divided
that by the number of draws. As there were 100
draws, the lowest empirical P-value of the combined
empirical P-value that could be obtained was <0.01,
when none of the combined empirical P-values from
the random draws was equal or more significant than
the combined empirical P-value from the synaptic
gene group (see Figure 1 for a graphical overview of
the steps in data analysis).
Enrichment tests of previously implicated genes
To test whether synaptic functional groups contained
previously implicated genes more often than by
chance, we retrieved all SNPs with Pp1.0–5 from
all significant loci reported in GWA studies for
schizophrenia that were published before 14 February
2011, using the GWAS catalog,
27 and mapped
these loci to protein-coding genes (NCBI build
v36.3). In addition, we added genes implicated from
genome-wide copy number variation studies. Fisher’s
exact tests were used to determine the presence of
enrichment.
Results
Are synaptic genes significantly associated with the
risk of schizophrenia?
No individual SNP reached the threshold for genome-
wide significance in any of the three data sets using a
genome-wide association analysis for each data set
separately (see Supplementary Material, Section 1).
Functional gene group analysis of all 1026 synaptic
genes jointly resulted in a significant association of
the total group of pre- and post-synaptic genes to the
risk of schizophrenia. This was true in all three
samples separately and highly significant when
combined across samples, with a combined P-value
of 7.6 10
 11. For each sample, the S-log(P) obtained
from the original analysis with all synaptic genes was
in the higher end of the empirical distribution and
highly significant with only one of 10000 permuta-
tions exceeding the observed S-log(P) for the ISC_
affy5, ISC_affy6 and GAIN data sets (see Figure 2).
Are synaptic genes more significantly associated with
the risk of schizophrenia than randomly drawn groups
of genes/genetic variants?
Results from the five control methods show that SNPs
in synaptic genes are more strongly associated with
the risk of schizophrenia than any other set of
randomly drawn genes. For none of the control
methods we found a combined empirical P-value that
was more significant than the combined empirical
P-value from the synaptic genes (see Figure 3). The
‘empirical P-value of the combined empirical P-value’
was <0.01 in all methods, suggesting that the group
of synaptic genes is generally more strongly asso-
ciated with schizophrenia than other groups of genes
that either include the same number of genes, the
same effective number of nongenic or genic SNPs,
nongenic SNPs only, genic SNPs only, or the same
Table 1 Five applied competitive control methods to test whether synaptic genes are more strongly associated with the risk for
schizophrenia than any other set of randomly grouped genes or single-nucleotide polymorphisms (SNPs)
Method Matched for SNPs drawn from Null hypothesis
1 Number of genes Genic SNPs, excluding SNPs
in synaptic genes
No more evidence for association in the
group of synaptic genes than any other set of
an equal number of genes
2 Effective number of SNPs Genic and nongenic SNPs,
excluding SNPs in synaptic
genes
No more evidence for association in the
group of synaptic genes than any other set of
an equal effective number of SNPs
3 Effective number of SNPs Genic SNPs, excluding SNPs
in synaptic genes
No more evidence for association in the
group of synaptic genes than any other set of
an equal effective number of genic SNPs
4 Effective number of SNPs Nongenic SNPs No more evidence for association in the
group of synaptic genes than any other set of
an equal effective number of nongenic SNPs
5 Effective number of SNPs Genic SNPs in genes
expressed in brain, excluding
SNPs in synaptic genes
No more evidence for association in the
group of synaptic genes than any other set of
an equal effective number of genic SNPs
from brain-expressed genes
Synaptic gene groups and schizophrenia
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genes only (see Supplementary Material, Section 2
and 3).
Which synaptic subgroups are most strongly related to
the risk of schizophrenia?
We tested 17 synaptic subgroups and one group of
synaptic genes that did not share a known function for
association with schizophrenia. We found that three
synaptic subgroups were significantly associated with
increased risk of schizophrenia under the null
hypothesis that none of the SNPs in these groups
were associated with schizophrenia: intracellular
signal transduction group (P=0.0002), genes related
to excitability (P=0.0009) and genes involved in CAT
signaling (P=0.0024) (see Table 2). The matched
control methods for these subgroups resulted in
P-values between 0.02 and 0.04 for the intracellular
signal transduction group, P-values between <0.01
and 0.03 for the excitability group and between 0.03
and 0.06 for the CATsignaling group (see Figure 3 and
Supplementary Material, Section 4).
The signal of the most significant functional group
(intracellular signal transduction) was mainly de-
rived from the two ISC samples, whereas the GAIN
sample contributed less to the overall evidence of
significance of these groups but contributed mostly to
association with the CAT signaling group. For the
Figure 1 Overview of steps in data analysis. The arrows in red represent the flow for the real data whereas the blue arrows
represent the flow for the control methods.
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independently showed nominally significant or sug-
gestive evidence. Quantile-quantile (Q-Q) plots (Sup-
plementary Figures S3a–c) of the significant
functional groups in the three samples show that for
each functional group a multitude of SNPs in multi-
ple genes, each of small effect, contribute to the
overall significance, suggesting that the association
cannot be explained by only a few genes in the group
but rather by the joint effect of many genes in the
functional group.
Synaptic subgroups include genes associated
previously with schizophrenia
We tested whether the synaptic functional groups
included genes for schizophrenia previously impli-
cated from GWAS or copy number variation studies.
The intracellular signal transduction group includes
NRGN that was one of the most significant genes
identified in the SGENEþ-based GWAS,
6 but was not
below the genome-wide threshold in the ISC or MGS
GWAS.
5 The excitability group contains CACNA1C,
which was one of the two most significant genes
identified in a recent GWAS for bipolar disorder,
28
and was recently also associated with schizophre-
nia.
29 From the group of genes involved in CAT
signaling, four genes were implicated previously in
schizophrenia. Enrichment analysis of previously
implicated genes in schizophrenia from GWAS and
copy number variation studies indicated significant,
although moderate, enrichment of previously asso-
ciated genes in the total group of synaptic genes
(P=0.02) using Fisher’s exact test (see Supplementary
Material, Section 5). This enrichment was mainly
because of enrichment in the CAT signaling group
(P=0.0002). However, three out of the four genes in
CAT signaling group that were implicated previously
were very large genes. As significant results from
GWAS studies may be biased toward large genes, the
enrichment test for the CAT signaling group needs to
be interpreted with caution.
Discussion
Our overarching goal was to test whether genetic
variation associated with schizophrenia risk accumu-
lates in functional gene groups operating in the
synapse. We showed that the total group of genes
encoding proteins in the synapse was highly asso-
ciated with the risk of developing schizophrenia with
a combined P-value of 7.6 10
 11. In addition, the
group of synaptic genes was more strongly associated
with schizophrenia than any of the matched-control
groups of genes (P<0.01). The functional gene group
approach is a novel approach in which genes are
grouped according to cellular function, and which
goes across traditionally defined biological pathways,
also referred to as horizontal versus vertical group-
ing.
11 We used a manually curated database of
functional gene groups, which tends to include more
Figure 3 Overview of combined empirical P-values from the total group of synaptic genes and the three subgroups that were
significant after correction for multiple testing, obtained from the analysis based on the actual functional gene groups (‘real’,
red bars), the five most significant results from the 100 draws for each control method (green bars) as well as the average
combined empirical P-value (blue bars) obtained from five control methods across 100 draws. Note that the combined
empirical P-values for the real group analysis as well as those for each of the 100 draws in 5 control methods are obtained
from 10000 permutations of the data and are the combined P-values across the three samples. For the ‘all synaptic genes’
group, none of the control methods resulted in a lower P-value than the real analysis (that is, all empirical P-values of the
empirical P-values <0.01), for the intracellular signal transduction group, control methods 1, 2, 3, 4, 5 resulted in empirical
P-values of the empirical P-values of 0.02, 0.04, 0.03, 0.04 and 0.03 respectively. For Excitability, this was 0.02, 0.03, <0.01,
<0.01 and 0.03, respectively, and for cell adhesion and trans-synaptic molecules signaling this was 0.03, 0.04, 0.04, 0.06 and
0.05, respectively. For description of competitive control methods and different null hypotheses tested we refer to Table 1.
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especially for genes expressed in brain—than some of
the online available databases. We do note, however,
that gene function annotation is an ongoing endeavor
and that annotation of functional gene groups is
therefore continuously improved.
Apart from testing all genetic variants in synaptic
genes as a group, we tested subgroups of synaptic
functioning and found that three subgroups of
synaptic functioning mainly drive the association of
the synaptic gene group with schizophrenia; intracel-
lular signal transduction (P=0.0002), excitability
(P=0.0009) and CATsignaling (P=0.0024). In general,
these associations were stronger than associations
with matched-control groups of genes, except for CAT
signaling (method 5, P=0.06), indicating that at least
some groups of similar size as the CATsignaling group
and existing of SNPs in brain-expressed genes are
more significantly associated with schizophrenia than
the CATsignaling group. We do note however that the
CAT signaling group overlaps with the cell adhesion
molecule pathway from the KEGG (Kyoto Encyclope-
dia of Genes and Genomes) database that was
previously associated with schizophrenia in the ISC.
12
The group of intracellular signal transduction was
most strongly associated with the risk of schizophre-
nia and includes the NRGN gene, which was one of
the most significant loci identified in the (indepen-
dent) SGENEþ GWAS,
6 but—as a single marker
effect—not below the threshold of significance in
the individual samples on which the current analysis
was based. In the samples included in our study, each
individual SNP in the intracellular signal transduc-
tion group contributed very little to the risk of
schizophrenia. However, combining their contribu-
tions resulted in a significant association.
Intracellular signal transduction in neurons and
synapses is characterized by a high degree of cross-
talk. A great variety of initial steps, such as activation
of many different cell membrane receptors, leads to
changes in a rather limited number of enzymes that
generate second messengers (adenylyl cyclase, phos-
pholipases) and a limited number of second messen-
gers inside the cell (calcium, cyclic adenosine-
monophosphate, cyclic guanosine monophosphate,
inositol 1,4,5-triphosphate; reviewed in de Jong and
Verhage
30). Hence, it is plausible that genetic varia-
tion in the genes encoding these factors has similar
biological consequences and additive contributions to
pathogenesis.
The second most significant functional group
(Excitability) regulates steady-state and action poten-
tial-induced ionic currents and membrane potential.
Many different channels can contribute but they all
allow a limited number of types of biologically
relevant ions to pass. Hence, as for the group of
intracellular signal transduction genes, it is plausible
that genetic variation in the genes encoding these
channels have similar biological consequences in
cellular excitability, and thus additive contributions
to pathogenesis.
For complex traits with evidence for large numbers
of variants of small effect size contributing to disease
risk—such as schizophrenia,
4,31 multiple sclerosis
32
and type 1 diabetes mellitus
33—it is of crucial
importance to test whether a reported association
with a group of genes is merely because of the
polygenic nature of the disease or the biological
function of that group of genes. Any large group of
genes is likely to emerge from pathway or functional
gene group analysis merely because of background
polygenic effects to the risk of disease. Reporting a
significant association with the group of synaptic
genes may therefore seem rather trivial, as it merely
confirms that synaptic genes are included in the
multitude of genes related to schizophrenia. A more
interesting question is thus whether the group of
synaptic genes is more strongly related to schizo-
phrenia than other randomly drawn groups of genes.
To test this, we designed five methods in which we
created matched-control groups of genetic variants.
As the genetic variants were drawn from different
pools, every control method tested slightly different
null hypotheses, providing insight into how impor-
tant an observed association with a group of genes is
under a polygenic model of inheritance. We propose
that such competitive tests for pathways or functional
groups need to be included in any future pathway or
functional gene group analysis.
In this study we investigated whether the accumu-
lated effects of genetic variants in multiple genes may
cause dysfunction of a biological system (for example,
intracellular signal transduction), while a single
genetic variant is not sufficient to cause disease.
The functional gene groups we defined are character-
ized by redundancy, which is most likely accom-
plished by previous gene duplication. Over time,
genetic mutations may arise causing different or less
optimal protein function, which may thrive in a gene
pool, thus leading to diversity or genetic heterogene-
ity. To some extent genes in the same functional group
may functionally replace each other when others
function suboptimal. Such redundancy and hetero-
geneity provide for fail-safe mechanisms, which
render functional gene groups—like most other
biological systems—robust. Robustness is a property
that allows a system to maintain its functions against
internal and external perturbations.
34,35
Typically, in different individuals a different set of
mutations may be responsible for dysfunction. As a
consequence, individuals with the same disease may
have completely different genetic backgrounds,
which is consistent with both a polygenic model of
disease and a threshold model of disease but seriously
hampers single-marker GWAS analysis, as it de-
creases the effect sizes of single SNPs/genes. When
focusing on a functional gene group, it becomes less
relevant which particular genes carry a mutation,
whereas the number of genes carrying a mutation
before the system starts to dysfunction is much more
important. Robustness, inherent to for instance
synaptic protein networks, and their underlying
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to interpret the notion that ‘thousands of genes under-
lie complex traits’ and may provide important insights
in the biological systems important in disease etiology
(see Supplementary Material, Section 6 and 7).
Our current results suggest that multiple genes
involved in synaptic functioning are important for
schizophrenia, provide support for the synaptic
hypothesis of schizophrenia
15–18 and provide tenta-
tive evidence for the involvement of the biological
mechanisms involved in intracellular signal trans-
duction, excitability and cell adhesion and trans-
synaptic signaling molecules in schizophrenia.
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